Log In
BCIQ
Print this Print this
 

sparsentan (RE-021) (formerly BMS-456567, PS433540)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionSmall molecule dual angiotensin and endothelin receptor antagonist (DARA)
Molecular Target Angiotensin receptor ; Endothelin receptor
Mechanism of ActionEndothelin receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationNephropathy
Indication DetailsTreat focal segmental glomerulosclerosis
Regulatory Designation U.S. - Orphan Drug (Treat focal segmental glomerulosclerosis);
EU - Orphan Drug (Treat focal segmental glomerulosclerosis)
PartnerLigand Pharmaceuticals Inc.;
Retrophin Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$76.2M

$1.2M

$75.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/18/2012

Undisclosed

Undisclosed

Undisclosed

02/27/2012

$76.2M

$1.2M

$75.0M

Get a free BioCentury trial today